MedTrace Logo

Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Exosomes in Treating Chronic Cough After COVID-19

NCT05808400 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-04-14

No results posted yet for this study

Summary

This clinical trial aims to evaluate the safety and effectiveness of umbilical cord mesenchymal stem cell (UCMSC)-derived extracellular vesicle nebulization inhalation therapy for the treatment of chronic cough after COVID-19 infection. The main objective is to assess whether UCMSC-derived exosome nebulization inhalation therapy alleviates chronic cough after COVID-19.

Participants will be asked to complete a questionnaire to help researchers evaluate their cough severity and to record their scores before nebulization inhalation of UCMSC-derived exosomes. Participants will receive either continuous nebulized inhalation of UCMSC-derived exosomes for 5 days, twice daily, or no treatment. Researchers will compare the experimental and control groups to evaluate the safety and efficacy of UCMSC-derived exosomes for the treatment of chronic cough after COVID-19 infection.

Conditions

  • Long COVID-19 Syndrome

Interventions

BIOLOGICAL

MSC-derived exosomes

The total volume of MSC-derived exosomes is 5ml, and exosome concentration in preparation is 1\*10\^9 particles/ml.

Sponsors & Collaborators

  • REGEN-αGEEK (SHENZHEN) MEDICAL TECHNOLOGY CO., LTD.

    collaborator UNKNOWN

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Jihui Du, PhD · Huazhong University of Science and Technology Union Shenzhen Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2024-02-15
Completion
2025-02-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05808400 on ClinicalTrials.gov